Background Dexamethasone improves outcome for some patients with bacterial meningitis, but not others. We aimed to identify which patients are most likely to benefi t from dexamethasone treatment.
Introduction
The yearly incidence of bacterial meningitis is estimated to be 2·6-6·0 cases per 100 000 in Europe and might be ten times higher in less developed countries. [1] [2] [3] [4] Experimental models have shown that outcome is related to the severity of the infl ammatory process in the subarachnoid space, and treatment with corticosteroids results in a reduction of the infl ammatory response and improved outcome. [5] [6] [7] These fi ndings have prompted several randomised controlled trials of corticosteroids for bacterial meningitis. 8 Initial results suggested that the main benefi cial eff ect of the corticosteroid dexamethasone was to reduce the risk of hearing loss in children with Haemophilus infl uenzae type b meningitis. 9 Additional data extended the likely benefi t to those with Streptococcus pneumoniae meningitis. 10 In 2004, a meta-analysis of fi ve randomised controlled trials showed that treatment with corticosteroids reduced both mortality and neurological sequelae in adults with bacterial meningitis, without detectable adverse eff ects. 11 Subsequently, a Cochrane meta-analysis of data from 20 randomised controlled trials and involving 2750 people showed an overall mortality benefi t and a reduction in neurological sequelae in patients treated with adjuvant corticosteroids. 8 However, three large randomised controlled trials published after this analysis showed confl icting results. [12] [13] [14] Adjunctive corticosteroids seem to benefi t some patients with bacterial meningitis but not others, and how to select patients who are likely to benefi t is unclear. Our aim was to address this question with a meta-analysis of data from fi ve major trials for which individual patient data were available.
Methods

Study selection
Relevant trials were identifi ed previously as part of a Cochrane review (fi gure 1). 8 Individual patient data from fi ve randomised, double-blind, placebo-controlled trials of dexamethasone for bacterial meningitis published since 2001 were included in the analysis; [12] [13] [14] [15] [16] individual patient data could not be acquired from the older trials. [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] The characteristics of the included studies are shown in table 1.
The study from South America used a 2×2 design to randomly assign children with bacterial meningitis to dexamethasone plus glycerol, dexamethasone plus placebo, glycerol plus placebo, or placebo plus placebo. 12 Data were available from children who were assigned dexamethasone plus placebo or placebo only but not from those who were given glycerol. During the study, the randomisation schedule was altered from a ratio of two dexamethasone per three placebo (randomisation schedule 1) to one dexamethasone per one placebo (randomisation schedule 2). Therefore, analyses from this study were stratifi ed according to randomisation schedule. The study in Malawian adults used a 2×2 design to randomly assign patients to dexamethasone or placebo and to intravenous or intramuscular ceftriaxone. 14 In all studies, patients were enrolled on the basis of clinically suspected bacterial meningitis and CSF criteria. All the studies used computer-generated randomisation to allocate patients to dexamethasone or placebo. Treatment concealment was adequate in all studies.
Defi nitions and outcome measures
The members of the study group met in October, 2006, and September, 2007, to discuss data sharing and the analysis plan, including the defi nitions of subgroups, which were specifi ed before the data were collated, the fi nal database created, and the analysis started. The principal investigators provided the raw data, which were checked by a statistician (PQT). Inconsistencies and outlying data were clarifi ed with the principal investigators and resolved from their raw data before the analysis.
15 data fi elds for each patient were selected for the analyses. The dataset included prognostic factors for unfavourable outcome and potential modifi ers of the treatment eff ect of dexamethasone, such as antibiotic treatment before admission, HIV infection, and malnutrition.
1,3 Defi nitions were agreed during the two study-group meetings. Values for continuous variables were reassigned into categories. Exposure to antibiotics before randomisation was defi ned by administration of eff ective oral or intravenous antibiotics within 48 h before the fi rst dose of study drug was received. Malnutrition was defi ned by individual investigators: patients who were not assessed were categorised according to the local prevalence of malnutrition. HIV tests were not done on every patient and an assessment was made of the likelihood of HIV infection based on local epidemiology. All untested Malawian adults were defi ned as likely to be HIV positive. No assumption was made for untested Malawian children. All other untested adults or children were defi ned as likely to be HIV negative. Impairment of consciousness was categorised by use of the Glasgow coma scale or the Blantyre coma score (table 2) . The causative pathogen was defi ned by CSF microscopy, CSF or blood culture, PCR, or latex agglutination.
The predetermined outcome measures were death at the time of fi rst follow-up; death or severe neurological sequelae (including severe bilateral hearing loss) at 1 month follow-up; death or any neurological sequelae (including any degree of hearing loss) at fi rst follow-up; and death or severe bilateral hearing loss at fi rst follow-up. The number of studies that contributed to each outcome is shown by degrees of freedom (df=number of studies minus 1). Additionally, as part of a post-hoc exploratory analysis and to analyse every possible endpoint of interest, we analysed hearing loss of any degree among survivors. The severity of neurological sequelae in the adult studies was defi ned using the Glasgow outcome score or the modifi ed Rankin scale. 28, 29 In the paediatric studies, severe neurological disability was defi ned as blindness, quadraparesis, hydrocephalus requir ing a shunt, or severe psychomotor retardation. Hearing loss was categorised as moderate or severe according to defi nitions used in the individual studies.
Statistical analysis
All analyses were stratifi ed according to study site (including two strata from the South American study) to account for any possible centre eff ect, including diff erences in mortality between centres. If appropriate, analyses were also stratifi ed according to the baseline variable of interest. Combined odds ratios (ORs) and tests for heterogeneity were calculated using conventional Mantel-Haenszel statistics. We also used exploratory analyses with logistic regression. The main purpose of the analysis was to establish whether dexamethasone had a diff erential eff ect in diff erent subgroups of patients; hence, heterogeneity between the subgroups (I² values) with signifi cance levels were calculated for each subgroup analysis. Tests for heterogeneity were calculated without 18 
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Results
The baseline characteristics were similar in placebo and dexamethasone groups within the fi ve studies (table 2). 1019 (50·2%) patients received dexamethasone and 1010 (49·8%) patients received placebo. 833 (41·1%) patients were less than 15 years old, of whom 415 received dexamethasone and 418 received placebo. 1196 adults (aged ≥15 years) were included, of whom 604 (50·5%) received dexamethasone and 592 (49·5%) received placebo. The ages of fi ve patients were unknown.
HIV co-infection was confi rmed in 549 (41·5%) of 1322 patients tested, of whom 391 (71·4%) were adults and 158 (28·8%) were children. An HIV test was not done in 707 (34·8%) patients but, on the basis of epidemiological risk, was judged likely to be positive in 31 untested adults from Malawi and negative in adults from Europe and children from South America. No assumption was made about 139 untested children from Malawi. In total, 286 confi rmed or likely HIVinfected patients received dexamethasone and 294 received placebo.
The diagnosis of bacterial meningitis was microbiologically confi rmed in 1639 (80·8%) patients and was most frequently caused by S pneumoniae (759 cases), H infl uenzae (297 cases), and Neisseria meningitidis (239 cases). The most common causative bacteria per study were as follows: Europe, N meningitis (38%); 16 Malawi (children), S pneumoniae (40%); 15 Vietnam, Streptococcus suis (32%); 13 Malawi (adults), S pneumoniae (59%); 14 and South America, H infl uenzae (47%). 12 Mortality in the placebo groups diff ered substantially between studies: 15% in Europe, 31% in Malawian children, 12% in Vietnam, 53% in Malawian adults, and 16% in South America.
Dexamethasone was not associated with a signifi cant reduction in death, death or severe neurological sequelae (including severe bilateral hearing loss), death or any neurological sequelae (including any hearing loss), or death or severe bilateral hearing loss, if all patients were included in the analysis (table 3) The subgroup analyses for all outcome measures are shown in fi gures 2 and 3, and the webappendix. Duration of symptoms before treatment, severity of coma at start of treatment, whether dexamethasone was given before or after antibiotics, and HIV infection status did not signifi cantly infl uence treatment response. Dexa methasone was more eff ective in patients aged older than Death, severe neurological sequelae, or audiological sequelae at hospital discharge BM=bacterial meningitis. *Dexamethasone was given before or with the fi rst dose of per-protocol parenteral antibiotic in all fi ve studies. †23% of patients received other antibiotic treatment. ‡2×2 design with patients randomly assigned to dexamethasone or placebo and to intravenous or intramuscular ceftriaxone. §2×2 design with patients randomly assigned to dexamethasone plus glycerol, dexamethasone plus placebo, placebo plus glycerol, or placebo plus placebo; patients assigned to receive glycerol with either dexamethasone or placebo were excluded from the individual patient data meta-analysis; data from this trial were analysed as two strata according to randomisation schedule. Data are number (%). *HIV serostatus was not available in patients in the European or South American trials; patients in these trials were assumed to be HIV negative. In the Vietnam trial, four untested patients were assumed to be HIV negative and in the Malawi adult trial, 31 untested patients were assumed to be HIV positive. In the Malawi paediatric trial, 139 (23%) patients were not tested and no assumption was made about their serostatus. Positive values only include patients tested and not those assumed to be positive. †Glasgow coma scale is categorised in adults as 15=normal, 11-14=mild impairment, 8-10=moderate impairment, 3-7=severe impairment. Blantyre coma score is categorised as 5=normal, 3-4=mild impairment, 2=moderate impairment, 0-1=severe impairment. ‡The use of urine reagent strips in the trials from Malawi provided semi-quantitative estimates of CSF glucose and protein. Protein and glucose concentrations were measured with a urine dipstick (Multistix 8SG Bayer), which provided colour-coded results of (protein/glucose) negative (0/0 mg/dL); trace (<30/100 mg/dL); 1+ (31-100/101-250 mg/dL); 2+ (101-300/251-500 mg/dL); 3+ (301-2000/501-1000 mg/dL); 4+ (>2000/>1000 mg/dL). did not show any consistent interaction between age and a treatment eff ect (data not shown). There was also no eff ect in a post-hoc analysis that restricted the study to patients treated with ceftriaxone (webappendix). The data were explored to identify evidence of heterogeneity between the studies. 23 subgroups were explored, each with fi ve diff erent endpoints. In patients with moderate CNS impairment on admission, there was some evidence of heterogeneity between three of the fi ve endpoints. In the subgroup of patients with moderate CNS impairment on admission, there was evidence of benefi t in death or severe neurological sequelae or bilateral hearing loss in the European study ( 
Discussion
The aim of this analysis was to establish whether any subgroups of patients with acute bacterial meningitis might benefi t from adjunctive dexamethasone and thereby explain any diff erences between individual trial results. Extensive exploration of 15 prespecifi ed subgroups did not show robust evidence that a particular subgroup would benefi t. The apparent benefi t in adults aged over 55 years might have occurred by chance. However, it is unclear whether it is more likely to have occurred by chance than the fi ndings of no benefi t in other subgroups.
This analysis of 2029 patients from fi ve trials showed that treatment with adjunctive dexamethasone did not signifi cantly reduce mortality, neurological disability, or severe hearing loss in bacterial meningitis. Combination of these results with those from older published trials, for which the raw data were not obtainable, did not show any evidence that dexamethasone was signifi cantly eff ective in reducing these outcomes overall. However, a post-hoc analysis on the incidence of deafness among survivors suggested that adjunctive dexamethasone treatment reduced the rate of hearing loss (OR 0·77 [95% CI 0·60-0·99; p=0·04), irrespective of whether patients had received antibiotics before dexamethasone treatment. The use of adjunctive dexamethasone treatment was not associated with an increased risk of adverse events.
Factors previously considered relevant to the decision to start dexamethasone treatment in patients with suspected or proven bacterial meningitis could not explain diff erences in results between the fi ve trials. These factors include duration of symptoms before treatment, severity of impaired consciousness at start of treatment, whether dexamethasone was given before or after antibiotics, and HIV infection status. 7, [36] [37] [38] [39] Because the results of the prespecifi ed analysis failed to show any signifi cant heterogeneity, extensive post-hoc analyses were done with the inclusion of an additional deafness endpoint. Such analyses are usually considered unreliable, particularly if no statistical allowance is made for multiple comparisons, because of the high chance of a false-positive result. However, the extra analyses were undertaken to allow the identifi cation of subgroups of interest for further possible study. These exploratory post-hoc analyses suggested a possible overall eff ect on deafness among survivors and on death and severe neurological sequelae in the subgroup of HIV-negative This meta-analysis is, as are all meta-analyses, limited by the possibility that more heterogeneity exists between the studies than has been identifi ed. If such heterogeneity were to exist, combining the studies would be inappropriate. Formal tests for heterogeneity between studies and between subgroups failed to show any convincing evidence of heterogeneity. However, such tests are insensitive and could miss important eff ects. We have therefore explored the data exhaustively for relevant subgroups of patients that could reveal possible causes of heterogeneity, although little such evidence was found.
On the basis of previous meta-analyses, 9 ,10 the administration of dexamethasone to children with H infl uenzae type b meningitis before the start of antibiotic therapy is thought to reduce the incidence of deafness. However, we found no evidence of a benefi t of adjunctive dexamethasone in all children or in any subgroup of children with this infection.
In summary, these data indicate that patients with bacterial meningitis neither benefi t from nor are harmed by treatment with adjunctive dexamethasone. Despite an individual patient data meta-analysis of more than 2000 patients, we have been unable to determine conclusively whether a subgroup of patients might benefi t. To establish with certainty whether dexamethasone has a place in the treatment of adult patients with bacterial meningitis, a large multinational randomised controlled trial would be necessary. This represents a formidable challenge and one that is not likely to be met for many years. In the meantime, we suggest the benefi t of adjunctive dexamethasone for all or any subgroup of patients with bacterial meningitis remains unproven and there is little support for its routine use in the treatment of this disease. Figure 4 : Eff ect of adjunctive dexamethasone therapy on death Trials included in the rest of this study [12] [13] [14] [15] [16] and other studies [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [30] [31] [32] [33] [34] [35] included in the Cochrane systematic review 8 are shown. OR=odds ratio. *Study 1 in Lebel. 24 †Study 2 in Lebel. 24
Contributors
The study was conceived by JJF. All the authors contributed to the study design and the selection of data for analysis. The analysis was done by PQT, TEP, and AHZ. The paper was written by DvdB, JJF, TEP, MS, and GET, with review and comment from all the authors.
Confl icts of interest
We have no confl icts of interest.
